Citius Oncology, Inc. filings document material-event disclosures for an oncology-focused biopharmaceutical company commercializing LYMPHIR™. Recent Form 8-K reports cover operating and financial results following the LYMPHIR launch, international shipment and distribution updates, clinical-study disclosures involving denileukin diftitox-cxdl, and press-release exhibits related to commercial and medical developments.
The filing record also includes emerging growth company disclosures, Nasdaq continued-listing notice reporting, and categories such as material agreements, shareholder voting matters, capital-structure disclosure, governance matters, and security-structure information. These documents frame CTOR’s public reporting around product commercialization, clinical development, corporate governance, listing compliance, and financing-related matters.
Suren G. Dutia, a director of Citius Oncology, acquired 300,000 restricted shares on 09/19/2025 at no cash price and reports beneficial ownership of 300,000 shares directly following the grant. The Form 4 also discloses two stock option holdings: a $1.07 exercise-price option for 125,000 shares granted 12/12/2024 that vests one-third annually, and a fully vested $2.15 exercise-price option for 150,000 shares. The restricted shares vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to continued service.
Citius Oncology director Eugene Myron Holuka acquired 300,000 restricted shares on 09/19/2025 and holds outstanding stock options totaling 275,000 shares. The restricted stock award was granted at no cash price and will vest in three substantially equal annual installments beginning one year after grant, subject to continued service. The reporting person also holds a $1.07 strike option for 125,000 shares (granted 12/12/2024, vesting 1/3 annually) and a fully vested $2.15 strike option for 150,000 shares. Following the reported transactions, the reporting person beneficially owns 300,000 shares and options on 275,000 shares directly.
Citius Oncology, Inc. (CTOR) filed a Registration Statement on Form S-8 to register securities for an employee benefit plan. The filing incorporates by reference the company’s prior annual and quarterly reports and certain current reports listed in the document, and cites a Certificate of Amendment to the Certificate of Incorporation filed in Delaware on April 7, 2025. The document contains the standard undertakings required for post-effective amendments and includes officer and director signatures dated September 19, 2025. The filing appears routine and relates to equity reserved for employee benefit plans rather than operational results.
Citius Oncology, Inc. reported that it issued warrants to a financial advisor to purchase up to 360,000 shares of common stock. These warrants have an exercise price of $2.1875 per share, become exercisable on March 10, 2026, and expire on March 10, 2031, and were issued in a private placement under Section 4(a)(2) of the Securities Act.
The board also approved an amendment to the company’s 2024 Omnibus Stock Incentive Plan, increasing the shares of common stock reserved for issuance under the plan from an aggregate of 15,000,000 shares to an aggregate of 30,000,000 shares. Aside from this increase in the share reserve, no other terms of the plan were changed.
Citius Pharmaceuticals, Inc. amended its Schedule 13D to reflect a registered direct offering on September 10, 2025 that issued 5,142,858 new common shares of Citius Oncology, Inc. After that issuance the reporting person, Citius Pharmaceuticals, Inc., beneficially owns 66,049,615 shares, representing approximately 79.1% of the issued and outstanding common stock based on a total of 83,513,442 shares. The filing states the reporting person has sole voting and dispositive power over those shares. The amendment updates prior Schedule 13D filings to give effect to the new issuance.